Amgen is planning to appeal a decision by the European Committee for Medicinal Products for Human Use to reject Vectibix for use against colorectal cancer that has spread to other parts of the body and not responded to chemotherapy. The FDA approved Vectibix last September and the biotech giant believes that its data on progression-free survival will ultimately win over the Europeans.
- here's the AP's report on Amgen
Related Story:
Vectibix delivers positive Phase III data. Report